The European Medicines Agency (EMA) has started a review of Lemtrada (alemtuzumab) following reports of side effects affecting the heart, blood vessels, liver and immune system. These side effects are rare but potentially serious.
As a temporary measure while the review is being carried out, the EMA has advised that Lemtrada should only be started in people with relapsing remitting MS that continues to be very active despite taking at least two disease modifying drugs (DMDs) or where other DMDs cannot be taken.
If you have already started Lemtrada and are due to receive further infusions, you should continue with treatment. Anyone who has been treated with Lemtrada should continue to have monthly blood and urine tests for four years after the last treatment course.
If you have concerns, you should talk to your neurologist or MS nurse.
MS in the Media
17 May 2019
- Statin has potential as SPMS drug
- EastEnders MS storyline
My Vespa adventure for the MS Trust
13 May 2019
For his next fundraising adventure, our supporter Nick Jolly will be riding 2,500 miles to Hungary on his Vespa scooter. He tells us about the inspiration behind his challenge.
"When you lose something, it makes you appreciate what you have"
13 May 2019
Danielle MacGillivray stars in our new film, Danielle. Here she tells us about her MS diagnosis, why she wanted to share her story in the film and learning to "appreciate the little things" every single day.